Quest PharmaTech, Inc. is a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company focuses on combinatorial immunotherapeutic approaches to cancer by using monoclonal antibodies of the immunoglobulin G or E subclass in combination with chemotherapy/immune-adjuvant. Its lead product candidate is Oregovomab, a monoclonal antibody, which is in Phase II clinical trial for the treatment of ovarian cancer. The firm also owns the Photodynamic therapy technology for oncology and dermatology applications; and develops Mab AR against truncated O-glycan on MUC16 for targeted cancer therapy applications. The company was founded in 1996 and is headquartered in Edmonton, Canada.